All Posts | Links Medicus - Free Medical News & Perspective

Review: Global accessibility of therapeutics for diabetes mellitus.

13 Feb, 2022 | 21:51h | UTC

Global accessibility of therapeutics for diabetes mellitus – Nature Reviews Endocrinology (if the link is paywalled, try this one)

New WHO report maps barriers to insulin availability and suggests actions to promote universal access – “100 years after its discovery, insulin still out of reach for many living with diabetes”.

Editorial | Insulin for all: a hope yet to be realized.

One hundred years of insulin therapy.

The state of diabetes treatment coverage in 55 low-income and middle-income countries – fewer than one in ten people with diabetes in LMICs receive comprehensive care such as low-cost medicines to reduce blood sugar, blood pressure and cholesterol levels, in addition to counseling on diet, exercise and weight.

Betibeglogene Autotemcel gene therapy for Non–beta0/beta0 Genotype beta-thalassemia.

13 Feb, 2022 | 21:46h | UTC

Betibeglogene Autotemcel Gene Therapy for Non–β⁰/β⁰ Genotype β-Thalassemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

Visual Abstract: Betibeglogene Autotemcel Gene Therapy for Non–β0/β0 Genotype β-Thalassemia. https://t.co/2GOCGxrruv pic.twitter.com/zLvuuuByXN

— NEJM (@NEJM) February 8, 2022

Aromatase inhibitors vs. tamoxifen in premenopausal women with estrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomized trials

13 Feb, 2022 | 21:32h | UTC

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials – The Lancet Oncology

Commentaries:

Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer – HealthDay

Aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in premenopausal as well as postmenopausal women – Cancer Research UK

Guideline for the management Herpes Simplex 1 and cosmetic interventions.

13 Feb, 2022 | 21:41h | UTC

Guideline for the Management Herpes Simplex 1 and Cosmetic Interventions – The Journal of Clinical and Aesthetic Dermatology

Guideline for the prevention, diagnosis, and management of acute bacterial soft tissue infections following nonsurgical cosmetic procedures.

13 Feb, 2022 | 21:40h | UTC

Guideline for the Prevention, Diagnosis, and Management of Acute Bacterial Soft Tissue Infections Following Nonsurgical Cosmetic Procedures – The Journal of Clinical and Aesthetic Dermatology

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections.

11 Feb, 2022 | 08:51h | UTC

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections – Clinical Microbiology and Infection

Original Guidelines:

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

Consensus opinion for the management of soft tissue filler induced vision loss.

13 Feb, 2022 | 21:36h | UTC

Consensus Opinion for The Management of Soft Tissue Filler Induced Vision Loss – The Journal of Clinical and Aesthetic Dermatology

AHA Scientific Statement | How does cannabis use affect brain health? Caution advised, more research needed.

11 Feb, 2022 | 08:53h | UTC

News Release: How does cannabis use affect brain health? Caution advised, more research needed – American Heart Association

Original Statement: Use of Marijuana: Effect on Brain Health: A Scientific Statement From the American Heart Association – Stroke

Commentary on Twitter

Use of Marijuana: Effect on Brain Health: A Scientific Statement From the American Heart Association #BrainHealth #ISC22 #AHAJournals https://t.co/LoGbVRfzf4 @American_Heart pic.twitter.com/DyNbFzA0Lw

— Stroke AHA/ASA (@StrokeAHA_ASA) February 10, 2022

RCT: Trametinib improves progression-free survival compared to standard of care in patients with recurrent low-grade serous ovarian cancer.

13 Feb, 2022 | 21:30h | UTC

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial – The Lancet

News Release: Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma – M. D. Anderson Cancer Center

Commentary on Twitter

Trial findings suggest MEK inhibitor, trametinib, represents new standard-of-care option for patients with recurrent low-grade serous carcinoma. https://t.co/69glZZdrZF pic.twitter.com/UHeccCj1Rn

— The Lancet (@TheLancet) February 10, 2022